Search results
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
Zacks via Yahoo Finance· 9 months agoRoche RHHBY announced that the European Commission (“EC”) had approved the label expansion for...
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Zacks via Yahoo Finance· 1 month agoIonis Pharmaceuticals IONS reported a loss of 98 cents per share for first-quarter 2024, which was...
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
Zacks via Yahoo Finance· 10 months agoIonis Pharmaceuticals IONS reported a loss of 60 cents per share for second-quarter 2023, which was...
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
Zacks via Yahoo Finance· 2 years agoIonis Pharmaceuticals IONS reported a loss of 33 cents per share in third-quarter 2022, narrower...
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
Zacks via Yahoo Finance· 1 year agoIonis Pharmaceuticals IONS reported a loss of 37 cents per share for fourth-quarter 2022, much...
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up
Zacks via Yahoo Finance· 1 year agoBiogen BIIB reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05, beating the...
What happens when a $2 million gene therapy is not enough
Reuters via Yahoo News· 10 months agoBaby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited...
Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace
Reuters via Yahoo Finance· 10 months agoBiogen Inc said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, to save costs as the company ramps up the launch of a new Alzheimer's disease drug in efforts ...
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
Zacks via Yahoo Finance· 2 years agoBiogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat...
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks via Yahoo Finance· 1 month agoBiogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key...